Implementation of TERT promoter mutations improve prognostication of the WHO classification in meningioma.

TERT promoter mutations have been associated with increased risk of recurrence in meningioma cohorts, thus a potential biomarker for aggressive phenotypes. A main purpose of refining tumour classification is better predictions on the patient level. We compiled data from previous published cohorts to investigate patient-level predictions of recurrence based on TERTp-mut status. Implementation of TERTp-mut into the WHO grading led to better patient prognostication by improved prediction of recurrence. Our results support implementation of TERTp-mut into diagnostics and classification of meningiomas. © 2021 British Neuropathological Society.

Citation

Christian Mirian, Kathrine Grell, Tareq A Juratli, Felix Sahm, Sabine Spiegl-Kreinecker, Matthieu Peyre, Annamaria Biczok, Jörg-Christian Tonn, Stéphane Goutagny, Luca Bertero, Andrea Daniela Maier, Lasse Rehné Jensen, Gabriele Schackert, Helle Broholm, David Scheie, Daniel P Cahill, Priscilla K Brastianos, Jane Skjøth-Rasmussen, Kåre Fugleholm, Morten Ziebell, Tina Nørgaard Munch, Bjarne Winther Kristensen, Tiit Mathiesen. Implementation of TERT promoter mutations improve prognostication of the WHO classification in meningioma. Neuropathology and applied neurobiology. 2022 Apr;48(3):e12773

Mesh Tags

Substances

PMID: 34799864

search → result